Trial Profile
A Phase III Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (KEYNOTE 183)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Pomalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-183; MK-3475-183/KEYNOTE-183
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 16 Oct 2021 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 01 Jun 2021 Results of post hoc subgroup analysis (n=27; Data cutoff date June 2, 2017) comparing the efficacy and safety of pembrolizumab plus pomalidomide and dexamethasone compared with pomalidomide and dexamethasone in Japanese patients, published in the International Journal of Hematology.
- 02 Dec 2020 Status changed from completed to discontinued.